Long-Acting Injectable Risperidone: Efficacy and Safety of the First Long-Acting Atypical Antipsychotic
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The authors assessed the efficacy and safety of the first long-acting atypical antipsychotic (long-acting injectable risperidone) in patients with schizophrenia. METHOD: In a 12-week, multicenter, double-blind, randomized study, patients received intramuscular injections every 2 weeks of placebo or long-acting risperidone (25 mg, 50 mg, or 75 mg). The primary measure of efficacy was the change in total score on the Positive and Negative Syndrome Scale. RESULTS: Of the 554 patients who were enrolled, 400 entered the double-blind study, and 370 received at least one postbaseline assessment. Mean changes in score of -6.2, -8.5, and -7.4 on the Positive and Negative Syndrome Scale were seen at endpoint for the 25-, 50-, and 75-mg risperidone groups, respectively; all three change scores were significantly different from that seen with placebo (+2.6). Improvements in positive and negative symptoms were also significantly greater in patients receiving risperidone. Long-acting risperidone was well tolerated. Adverse events related to extrapyramidal symptoms were spontaneously reported by 13% of patients receiving placebo and 10% of patients in the 25-mg risperidone group, with higher rates in the 50-mg and 75-mg groups. Severity of extrapyramidal symptoms was mild at baseline and throughout the trial in each treatment group. Mean weight changes were small in the 25-, 50-, and 75-mg risperidone groups (0.5 kg, 1.2 kg, and 1.9 kg, respectively). Injection site pain was rated as low by the patients, consistent with the investigators' pain ratings. CONCLUSIONS: Long-acting injectable risperidone was efficacious and well tolerated and provides both clinicians and patients with a new mode of treatment that can improve the outcome of long-term therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
Hapeman, D. E. (1991) · Technometrics · doi:10.1080/00401706.1991.10484817 · Cited by 9,373
Searle, S. R., & Searle, S. R. (1971) · Cited by 3,229
Statistical Methods for Survival Data Analysis.
Lachenbruch, P. A., & Lee, E. T. (1993) · Journal of the American Statistical Association · doi:10.2307/2290742 · Cited by 2,845
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Robinson, D., Woerner, M. G., Alvir, J. M. J., Bilder, R., Goldman, R., Geisler, S., Koreen, A., Sheitman, B., Chakos, M., Mayerhoff, D., et al. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.3.241 · Cited by 1,327
Multiple Comparisons: Theory and Methods
Christensen, R. (1997) · Technometrics · doi:10.1080/00401706.1997.10485097 · Cited by 1,098
Marder, S. R., Davis, J. M., & Chouinard, G. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n1205 · Cited by 759
Compliance With Medication Regimens for Mental and Physical Disorders
Cramer, J. A., & Rosenheck, R. (1998) · Psychiatric Services · doi:10.1176/ps.49.2.196 · Cited by 725
Statistical Methods for Survival Data Analysis.
Saggu, P. S., & Lee, E. T. (1994) · The Statistician · doi:10.2307/2348154 · Cited by 628
Csernansky, J. G., Mahmoud, R., & Brenner, R. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa002028 · Cited by 605 · cited 1×
“In a recent landmark study, however, rates of relapse during 1 year of treatment were significantly lower in patients with schizophrenia receiving risperidone than in patients receiving the most widely used conventional antipsychotic, haloperidol (17).”
BackgroundAntipsychotic Medication Adherence: Is There a Difference Between Typical and Atypical Agents?
Dolder, C. R., Lacro, J. P., Dunn, L. B., & Jeste, D. V. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.1.103 · Cited by 386
Guidelines for depot antipsychotic treatment in schizophrenia
Kane, J. M., Aguglia, E., Altamura, A. C., Gutierrez, J. L. A., Brunello, N., Fleischhacker, W. W., Gaebel, W., Gerlach, J., Guelfi, J.-D., Kissling, W., et al. (1998) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(97)00045-x · Cited by 332
Self-citationDepot Antipsychotic Drugs: Place in Therapy
Davis, J. M., Metalon, L., Watanabe, M. D., & Blake, L. (1994) · Drugs · doi:10.2165/00003495-199447050-00004 · Cited by 295
Systematic meta-review of depot antipsychotic drugs for people with schizophrenia
Adams, C. E., Fenton, M. K. P., Quraishi, S., & David, A. S. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.179.4.290 · Cited by 288
Cochrane, G. M., Horne, R., & Chanez, P. (1999) · Respiratory Medicine · doi:10.1016/s0954-6111(99)90260-3 · Cited by 246 · cited 1×
“Partial compliance is common among patients with schizophrenia (11), as in other diseases requiring long-term treatment (12, 13).”
BackgroundAtypical Antipsychotics Part I: Pharmacology, Pharmacokinetics, and Efficacy
Markowitz, J. S., Brown, C. S., & Moore, T. R. (1999) · Annals of Pharmacotherapy · doi:10.1345/aph.17215 · Cited by 208
Systematic review of patient and nurse attitudes to depot antipsychotic medication
Walburn, J., Gray, R., Gournay, K., Quraishi, S., & David, A. S. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.179.4.300 · Cited by 187
Long Term Depot Antipsychotics
Barnes, T. R. E., & Curson, D. A. (1994) · Drug Safety · doi:10.2165/00002018-199410060-00005 · Cited by 130
Atypical Antipsychotics: Part II Adverse Effects, Drug Interactions, and Costs
Brown, C., Markowitz, J. S., Moore, T. R., & Parker, N. G. (1999) · Annals of Pharmacotherapy · doi:10.1345/aph.17216 · Cited by 105
Bloch, Y., Mendlovic, S., Strupinsky, S., Altshuler, A., Fennig, S., & Ratzoni, G. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n1104 · Cited by 99
Compliance with Antihypertensive Treatment
Costa, F. V. (1996) · Clinical and Experimental Hypertension · doi:10.3109/10641969609088977 · Cited by 75
A Multidose Study of Haloperidol Decanoate in the Maintenance Treatment of Schizophrenia
Kane, J. M., Davis, J. M., Schooler, N. R., Marder, S. R., Casey, D. E., Brauzer, B., Mintz, J., & Conley, R. R. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.4.554 · Cited by 67
Self-citationMarder, S. R., Midha, K. K., Putten, T. V., Aravagiri, M., Hawes, E. M., Hubbard, J. W., McKay, G., & Mintz, J. (1991) · The British Journal of Psychiatry · doi:10.1192/bjp.158.5.658 · Cited by 56
Nayak, R. K., Doose, D. R., & Nair, N. P. V. (1987) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1987.tb02175.x · Cited by 55
Depot Neuroleptic Therapy: Clinical Considerations
Gary, J. R., & Martha, E. A. (1995) · The Canadian Journal of Psychiatry · doi:10.1177/070674379504003s02 · Cited by 50
The Need for Depot A typical Antipsychotics in the U.S.
Shen, W. W. (1998) · Psychiatric Services · doi:10.1176/ps.49.6.727 · Cited by 12
Cited by
Kahn, R. S., Sommer, I. E., Murray, R. M., Meyer-Lindenberg, A., Weinberger, D. R., Cannon, T. D., O'Donovan, M., Correll, C. U., Kane, J. M., van Os, J., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.67 · Cited by 1,124
Self-citationDrucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070
The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements
Buchanan, R. W., Kreyenbuhl, J., Kelly, D. L., Noel, J. M., Boggs, D. L., Fischer, B. A., Himelhoch, S., Fang, B., Peterson, E., Aquino, P. R., et al. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp116 · Cited by 907
Manual for the Extrapyramidal Symptom Rating Scale (ESRS)
Chouinard, G., & Margolese, H. C. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.02.013 · Cited by 416
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & WFSBP Task force on Treatment Guidelines for Schizophrenia (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.739708 · Cited by 416
Metadata
- Authors
- Kane, J. M., Eerdekens, M., Lindenmayer, J.-P., Keith, S. J., Lesem, M., & Karcher, K.
- Venue
- American Journal of Psychiatry
- Published
- 2003-06-01
- Volume
- 160
- Issue
- 6
- Pages
- 1125-1132
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2107962758
- Cited by
- 489
- References
- 27
- FWCI
- 25.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.